Patient and caregiver benefit‐risk preferences for nonmetastatic castration‐resistant prostate cancer treatment
S Srinivas, AF Mohamed, S Appukkuttan… - Cancer …, 2020 - Wiley Online Library
Background Recently approved second‐generation androgen receptor inhibitors (SGARIs)
for non‐metastatic castration‐resistant prostate cancer (nmCRPC) have similar efficacy but …
for non‐metastatic castration‐resistant prostate cancer (nmCRPC) have similar efficacy but …
Drug–drug interaction potential among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with novel androgen receptor inhibitors
S Appukkuttan, G Ko, C Fu, B Bannister… - Expert Review of …, 2024 - Taylor & Francis
Background Nonmetastatic castration-resistant prostate cancer (nmCRPC) patients are often
older and use concurrent medications that increase the potential for drug–drug interactions …
older and use concurrent medications that increase the potential for drug–drug interactions …
Real-world incidence and burden of adverse events among non-metastatic prostate cancer patients treated with secondary hormonal therapies following androgen …
A Shah, R Shah, N Kebede, A Mohamed… - Journal of Medical …, 2020 - Taylor & Francis
Aims: To describe the incidence and identify prognostic factors of central nervous system
(CNS) adverse events (AEs) and any AEs (CNS, skin rash, or fracture) and evaluate the …
(CNS) adverse events (AEs) and any AEs (CNS, skin rash, or fracture) and evaluate the …
Treatment characteristics for nonmetastatic castration-resistant prostate cancer in the United States, Europe and Japan
R Shah, M Botteman, R Waldeck - Future Oncology, 2019 - Taylor & Francis
Aim: We conducted this study to describe nonmetastatic castration-resistant prostate cancer
(nmCRPC) patient characteristics and treatment patterns in the US, Europe and Japan …
(nmCRPC) patient characteristics and treatment patterns in the US, Europe and Japan …